EpiVax
@epivax.bsky.social
EpiVax leads the industry in immunogenicity assessment and sequence optimization for biologic therapeutics and vaccines.
Can circulating tumor cells replace tumor biopsies for neoantigen discovery?
This study explores a minimally invasive approach using apheresis, flow cytometry, and exome sequencing to identify neoantigens from CTCs in advanced-stage cancer patients.
More here:
www.frontiersin.org/journals/imm...
This study explores a minimally invasive approach using apheresis, flow cytometry, and exome sequencing to identify neoantigens from CTCs in advanced-stage cancer patients.
More here:
www.frontiersin.org/journals/imm...
Frontiers | A method for identifying neoantigens through isolation of circulating tumor cells using apheresis among patients with advanced-stage cancer
BackgroundImmune checkpoint inhibitors show limited efficacy in tumors with low tumor mutational burden, partly due to insufficient neoantigen presentation.M...
www.frontiersin.org
July 15, 2025 at 1:31 PM
Can circulating tumor cells replace tumor biopsies for neoantigen discovery?
This study explores a minimally invasive approach using apheresis, flow cytometry, and exome sequencing to identify neoantigens from CTCs in advanced-stage cancer patients.
More here:
www.frontiersin.org/journals/imm...
This study explores a minimally invasive approach using apheresis, flow cytometry, and exome sequencing to identify neoantigens from CTCs in advanced-stage cancer patients.
More here:
www.frontiersin.org/journals/imm...
Reposted by EpiVax
Super postdoc @chadbrambley.bsky.social killing it at the AI/HI Immunoinformatics workshop, telling us about finding molecular mimics of antigenic epitopes. Thanks to @epivax.bsky.social for the invitation and opportunity!
June 6, 2025 at 3:48 PM
Super postdoc @chadbrambley.bsky.social killing it at the AI/HI Immunoinformatics workshop, telling us about finding molecular mimics of antigenic epitopes. Thanks to @epivax.bsky.social for the invitation and opportunity!
The latest Epi-paper is out!
We studied a peptide-based COVID-19 booster in a mostly Hispanic American cohort to address gaps in representation. The findings support durable T cell immunity and a step toward greater health equity in vaccine research.
bit.ly/4mDCvv5
We studied a peptide-based COVID-19 booster in a mostly Hispanic American cohort to address gaps in representation. The findings support durable T cell immunity and a step toward greater health equity in vaccine research.
bit.ly/4mDCvv5
T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine
This study reports the pre-clinical evaluation of peptides from EPV-CoV-19, a T cell epitope-based SARS-CoV-2 vaccine candidate, following spike-mRNA vaccination of a predominantly Hispanic America...
www.tandfonline.com
May 29, 2025 at 2:54 PM
The latest Epi-paper is out!
We studied a peptide-based COVID-19 booster in a mostly Hispanic American cohort to address gaps in representation. The findings support durable T cell immunity and a step toward greater health equity in vaccine research.
bit.ly/4mDCvv5
We studied a peptide-based COVID-19 booster in a mostly Hispanic American cohort to address gaps in representation. The findings support durable T cell immunity and a step toward greater health equity in vaccine research.
bit.ly/4mDCvv5
We’re excited to finally share: Dr. Vibha Jawa is EpiVax’s new Chief Scientific Officer.
She’s a powerhouse in immunogenicity science with 20+ years of experience in biologics, vaccines, and gene therapy.
Big things ahead. Welcome, Vibha!
Full announcement: epivax.com/epivax-appoi...
She’s a powerhouse in immunogenicity science with 20+ years of experience in biologics, vaccines, and gene therapy.
Big things ahead. Welcome, Vibha!
Full announcement: epivax.com/epivax-appoi...
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO - EpiVax
EpiVax announces the appointment of Chief Scientific Officer (CSO), Vibha Jawa PhD, FAAPS to lead scientific strategy of the company.
epivax.com
May 28, 2025 at 5:42 PM
We’re excited to finally share: Dr. Vibha Jawa is EpiVax’s new Chief Scientific Officer.
She’s a powerhouse in immunogenicity science with 20+ years of experience in biologics, vaccines, and gene therapy.
Big things ahead. Welcome, Vibha!
Full announcement: epivax.com/epivax-appoi...
She’s a powerhouse in immunogenicity science with 20+ years of experience in biologics, vaccines, and gene therapy.
Big things ahead. Welcome, Vibha!
Full announcement: epivax.com/epivax-appoi...
As antibodies mature, they lose regulatory T cell epitopes while keeping effector signals. Read about our latest study for a new lens on immune tolerance, autoimmunity, and antibody design.
🧬 bit.ly/42G0voc
#immunology #antibodies
🧬 bit.ly/42G0voc
#immunology #antibodies
Frontiers | Regulatory T cell epitope content in human antibodies decreases during maturation
www.frontiersin.org
April 21, 2025 at 3:22 PM
As antibodies mature, they lose regulatory T cell epitopes while keeping effector signals. Read about our latest study for a new lens on immune tolerance, autoimmunity, and antibody design.
🧬 bit.ly/42G0voc
#immunology #antibodies
🧬 bit.ly/42G0voc
#immunology #antibodies
🚨 EpiVax has filed a Model Master File (MMF) for our PANDA® In Silico Model with the FDA, helping to streamline ANDA filings. Learn more about our approach to assessing the immunogenicity of generic peptide drugs in this new publication: 🔗 link.springer.com/article/10.1...
Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches - Pharmaceutical Research
Generic drugs have saved consumers billions of dollars in the United States. The demand for lower-cost and effective drugs, particularly for well-known peptide drugs like Ozempic and Wegovy (brand nam...
link.springer.com
March 26, 2025 at 2:01 PM
🚨 EpiVax has filed a Model Master File (MMF) for our PANDA® In Silico Model with the FDA, helping to streamline ANDA filings. Learn more about our approach to assessing the immunogenicity of generic peptide drugs in this new publication: 🔗 link.springer.com/article/10.1...